We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
Read MoreHide Full Article
Key Takeaways
Waters partners with Labcorp to expand access to the FDA-approved BD Onclarity HPV Assay by late 2026.
Labcorp's network of 850,000-plus providers and 2,200 centers could boost Waters' HPV test adoption.
The assay detects six high-risk HPV types, aids personalized risk assessment and cervical cancer screening.
Waters (WAT - Free Report) recently announced a partnership with Labcorp Holdings Inc. (LH - Free Report) to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network, beginning in late 2026. The collaboration aims to broaden cervical cancer screening options by making the test available through clinician-collected and self-collected samples in clinics, patient service centers and at-home settings.
Waters’ management highlighted that the partnership could help address barriers to cervical cancer screening, including privacy, access and socioeconomic factors. The collaboration aims to expand access through more flexible screening options and personalized risk assessment to reach underserved populations and close existing gaps in preventive care.
WAT Stock Trend Following the News
WAT stock has inched up 0.5% since the announcement on Friday. Year to date, the stock has gained 20.1%, outperforming the industry’s 1% decline and the S&P 500’s 11.3% rise.
The partnership could support WAT’s growth by expanding the commercial reach of its advanced diagnostics portfolio through Labcorp’s extensive healthcare network. Wider access to the BD Onclarity HPV Assay may encourage greater adoption of its testing technology among healthcare providers and patients seeking convenient screening options. The collaboration could also strengthen Waters’ position in molecular diagnostics by connecting its testing capabilities with established laboratory and consumer healthcare channels, creating opportunities to increase demand as screening programs expand.
WAT currently has a market capitalization of $44.57 billion.
Image Source: Zacks Investment Research
More on the News
The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines through comprehensive extended genotyping. It individually identifies six high-risk HPV types — 16, 18, 31, 45, 51 and 52 — alongside three groups of pooled results, providing detailed information to help guide patient management.
Under the partnership, Labcorp intends to offer the assay through its network, which serves more than 850,000 physicians and healthcare providers and over 2,200 patient service centers. Testing will be available through clinician programs, health plan Gaps in Care initiatives and Labcorp OnDemand, its consumer-facing testing channel. The combination of clinician-collected and self-collected screening options is intended to make testing more accessible to women who may otherwise delay or miss recommended screening.
The collaboration comes as cervical cancer screening remains an important preventive healthcare need, with many women overdue for recommended testing. High-risk HPV genotypes are associated with cervical cancer, making detailed genotype information valuable for assessing risk and guiding follow-up care.
Waters and Labcorp intend to make the BD Onclarity HPV Assay available through the expanded offering by the end of 2026. The partnership could broaden the reach of Waters’ diagnostics technology, with its eventual commercial impact depending on test adoption and utilization across Labcorp’s network.
Industry Prospects Favoring the Market
According to Grand View Research, the global human papillomavirus (HPV) testing market is estimated to be valued at $2.2 billion in 2026 and is expected to witness a CAGR of 14.4% through 2033.
Factors such as the rising prevalence of HPV-related cancers, growing awareness of cervical cancer screening, increasing adoption of advanced molecular diagnostic technologies and expanding access to self-collection testing options are expected to drive market growth.
Other News
Waters recently partnered with Quest Diagnostics to expand nationwide access to the FDA-cleared Onclarity Self-Collection Kit for at-home HPV screening. Beginning in 2027, Quest Diagnostics will offer the option through clinician, health plan, consumer health and patient service center channels, helping address barriers to cervical cancer screening.
Waters also launched AI Link, integrating Anthropic’s Model Context Protocol into its waters_connect software to enable AI-driven laboratory workflows. The technology allows scientists to control instruments using AI agents, automate experiments and accelerate research and development, with workflows extending into regulated environments.
OPKO Health reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
View the Zacks #1 Rank List
Image: Bigstock
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
Key Takeaways
Waters (WAT - Free Report) recently announced a partnership with Labcorp Holdings Inc. (LH - Free Report) to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network, beginning in late 2026. The collaboration aims to broaden cervical cancer screening options by making the test available through clinician-collected and self-collected samples in clinics, patient service centers and at-home settings.
Waters’ management highlighted that the partnership could help address barriers to cervical cancer screening, including privacy, access and socioeconomic factors. The collaboration aims to expand access through more flexible screening options and personalized risk assessment to reach underserved populations and close existing gaps in preventive care.
WAT Stock Trend Following the News
WAT stock has inched up 0.5% since the announcement on Friday. Year to date, the stock has gained 20.1%, outperforming the industry’s 1% decline and the S&P 500’s 11.3% rise.
The partnership could support WAT’s growth by expanding the commercial reach of its advanced diagnostics portfolio through Labcorp’s extensive healthcare network. Wider access to the BD Onclarity HPV Assay may encourage greater adoption of its testing technology among healthcare providers and patients seeking convenient screening options. The collaboration could also strengthen Waters’ position in molecular diagnostics by connecting its testing capabilities with established laboratory and consumer healthcare channels, creating opportunities to increase demand as screening programs expand.
WAT currently has a market capitalization of $44.57 billion.
Image Source: Zacks Investment Research
More on the News
The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines through comprehensive extended genotyping. It individually identifies six high-risk HPV types — 16, 18, 31, 45, 51 and 52 — alongside three groups of pooled results, providing detailed information to help guide patient management.
Under the partnership, Labcorp intends to offer the assay through its network, which serves more than 850,000 physicians and healthcare providers and over 2,200 patient service centers. Testing will be available through clinician programs, health plan Gaps in Care initiatives and Labcorp OnDemand, its consumer-facing testing channel. The combination of clinician-collected and self-collected screening options is intended to make testing more accessible to women who may otherwise delay or miss recommended screening.
The collaboration comes as cervical cancer screening remains an important preventive healthcare need, with many women overdue for recommended testing. High-risk HPV genotypes are associated with cervical cancer, making detailed genotype information valuable for assessing risk and guiding follow-up care.
Waters and Labcorp intend to make the BD Onclarity HPV Assay available through the expanded offering by the end of 2026. The partnership could broaden the reach of Waters’ diagnostics technology, with its eventual commercial impact depending on test adoption and utilization across Labcorp’s network.
Industry Prospects Favoring the Market
According to Grand View Research, the global human papillomavirus (HPV) testing market is estimated to be valued at $2.2 billion in 2026 and is expected to witness a CAGR of 14.4% through 2033.
Factors such as the rising prevalence of HPV-related cancers, growing awareness of cervical cancer screening, increasing adoption of advanced molecular diagnostic technologies and expanding access to self-collection testing options are expected to drive market growth.
Other News
Waters recently partnered with Quest Diagnostics to expand nationwide access to the FDA-cleared Onclarity Self-Collection Kit for at-home HPV screening. Beginning in 2027, Quest Diagnostics will offer the option through clinician, health plan, consumer health and patient service center channels, helping address barriers to cervical cancer screening.
Waters also launched AI Link, integrating Anthropic’s Model Context Protocol into its waters_connect software to enable AI-driven laboratory workflows. The technology allows scientists to control instruments using AI agents, automate experiments and accelerate research and development, with workflows extending into regulated environments.
Waters Corporation Price
Waters Corporation price | Waters Corporation Quote
WAT’s Zacks Rank & Key Picks
Currently, Waters carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) and Intuitive Surgical (ISRG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPKO Health reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.